Acquisition Opportunity – Aurena’s Partner Mucocort AB is for Sale

Karlstad, Sweden: – For several years, Aurena Laboratories has collaborated with the Swedish MedTech innovator Mucocort AB. Mucocort has developed a patented mucoadhesive patch designed to provide immediate pain relief and promote accelerated healing for Recurrent Aphthous Stomatitis (RAS) – the leading cause of oral ulcers, affecting up to 20% of the global population.

Aurena’s role in the collaboration has been to support product development, regulatory strategy for CE marking, and enable manufacturing of the product. This is now an exciting time for both Aurena and Mucocort, as the project and company are being prepared for acquisition.

Mucocort has engaged Experia Corporate Finance as exclusive financial advisors to identify a strategic acquirer – ideally a partner with established commercial infrastructure in MedTech, oral care, or consumer health, with existing marketing and distribution capabilities.

Magnus Hedman, Chairman of the Board at Aurena Laboratories, commented:

“This is a great opportunity for an established commercial player to take a validated innovation and turn it into a globally accessible product—we’re proud to have been part of the development journey.”

If you are interested in this opportunity, please contact Experia Corporate Finance using the details provided in the attached summary (see Resources).

About Aurena Laboratories

Swedish-based Aurena Laboratories (Aurena) specializes in the development and manufacturing of products using Bag-on-Valve packaging. The company is a leader in private label products and contract manufacturing of bag-on-valve aerosols for the pharmaceutical and medical device industry.

Their products offer private label seawater/saline-based nasal sprays, wound wash sprays, adhesive removers, and burn gels. Aurena-manufactured products are brought to market under Private Label or as contract-manufactured products.

More information is available at: www.aurenalabs.com

About Mucocort AB

Mucocort AB, founded in 2016, is a Swedish MedTech innovator based at the Umeå Biotech Incubator, a leading center for life science research. The company focuses on developing NextGen treatments for Recurrent Aphthous Stomatitis (RAS), a painful and highly prevalent condition affecting the oral mucosa.

Mucocort is currently in a pre-commercial phase, operating as a virtual organization supported by its founders, a senior network of experts across medical device development, manufacturing, clinical trials, regulatory affairs, and IP protection.

Its flagship product, internal project name M045A, is a first-in-class, biodegradable, mucoadhesive patch engineered for direct application to oral ulcers. Classified as a Class IIa medical device, the patch delivers immediate pain relief, symptom reduction, and accelerated mucosal healing through a dual mechanism: Hygroscopic effect (absorbing wound exudate) and Nonpharmacological antimicrobial and anti-inflammatory action (suppressing cytokines IL-2 and TNF- α). The patch forms a biocompatible gel barrier that naturally dissolves within 3–4 hours, offering a drug-free, steroid-free, and patient-friendly treatment.

Patents on MO45A have been granted in Europe, China, Australia, and Japan with protection extending until 2040.

Mucocort operates under ISO 13485 standards and has obtained regulatory approval in Sweden to initiate clinical trials according to ISO 14155, ISO 10993 and ISO 13485. Ongoing studies are assessing safety and effectiveness, supporting CE marking and future commercialization strategies.

Resources

Click on Executive Summary – Mucocort AB to learn more.
Click on Mucocort – Oral patch for instant pain relief and faster healing of Recurrent Aphthous Ulcers (RAS) for further information.